Jump to content

Search the hub

Showing results for tags 'Data'.


More search options

  • Search By Tags

    Start to type the tag you want to use, then select from the list.

  • Search By Author

Content Type


Forums

  • All
    • Commissioning, service provision and innovation in health and care
    • Coronavirus (COVID-19)
    • Culture
    • Improving patient safety
    • Investigations, risk management and legal issues
    • Leadership for patient safety
    • Organisations linked to patient safety (UK and beyond)
    • Patient engagement
    • Patient safety in health and care
    • Patient Safety Learning
    • Professionalising patient safety
    • Research, data and insight
    • Miscellaneous

Categories

  • Commissioning, service provision and innovation in health and care
    • Commissioning and funding patient safety
    • Digital health and care service provision
    • Health records and plans
    • Innovation programmes in health and care
  • Coronavirus (COVID-19)
    • Blogs
    • Data, research and statistics
    • Frontline insights during the pandemic
    • Good practice and useful resources
    • Guidance
    • Mental health
    • Exit strategies
    • Patient recovery
  • Culture
    • Bullying and fear
    • Good practice
    • Occupational health and safety
    • Safety culture programmes
    • Second victim
    • Speak Up Guardians
    • Staff safety
    • Whistle blowing
  • Improving patient safety
    • Clinical governance and audits
    • Design for safety
    • Disasters averted/near misses
    • Equipment and facilities
    • Error traps
    • Human factors (improving human performance in care delivery)
    • Improving systems of care
    • Implementation of improvements
    • Safety stories
    • Stories from the front line
    • Workforce and resources
  • Investigations, risk management and legal issues
  • Leadership for patient safety
  • Organisations linked to patient safety (UK and beyond)
  • Patient engagement
  • Patient safety in health and care
  • Patient Safety Learning
  • Professionalising patient safety
  • Research, data and insight
  • Miscellaneous

News

  • News

Find results in...

Find results that contain...


Date Created

  • Start
    End

Last updated

  • Start
    End

Filter by number of...

Joined

  • Start

    End


Group


First name


Last name


Country


About me


Organisation


Role

Found 24 results
  1. Event
    This webcast provides a tutorial on the AHRQ Surveys on Patient Safety Culture™ (SOPS®) Data Entry and Analysis Tool. Speakers will demonstrate how you can enter your SOPS survey data into the tool and it will automatically create tables and graphs to display your survey results. The tool allows healthcare organisations to compare results to the data in SOPS Databases. Register
  2. News Article
    A drug used to treat rheumatoid arthritis appears to help patients who are admitted to intensive care with the most severe coronavirus infections, researchers say. Tocilizumab, a medicine that dampens down inflammation, improved outcomes for critically ill patients, according to early results from an international trial investigating whether the drug and others like it boost survival rates and reduce the amount of time patients spend in intensive care. The findings have not been peer-reviewed or published in a journal, but if confirmed by more trial data, the drug will be on track to become only the second effective therapy for the sickest Covid patients, following positive results for the steroid dexamethasone earlier this year. “We think these are very exciting results, we are encouraged by them,” said Prof Anthony Gordon, of Imperial College London, the UK’s chief investigator on the REMAP-CAP trial. “It could become the standard of care once we have all the data reviewed by guidelines groups, and also drug regulators.” Read full story Source: The Guardian, 20 November 2020
  3. News Article
    An official review carried out for the health secretary, leaked to HSJ, reveals plans to bolster the law to require greater sharing of patient data, saying it would help improve safety for those wrongly prescribed drugs. A draft of the report on overprescribing, carried out for Matt Hancock by NHS England, says a major problem is that clinicians in different parts of the system can’t see what’s been prescribed and dispensed elsewhere. It says “wider access” should be given, which would also ensure “many eyes” are looking at the data to detect patterns or problems. This should include making it a requirement that prescribing apps make their data openly available, according to the report by chief pharmaceutical officer Keith Ridge. Read full story (paywalled) Source: HSJ, 16 November 2020
  4. News Article
    Pfizer and BioNTech have said that their coronavirus vaccine may be more than 90% effective, after the two pharmaceutical firms released interim data from their ongoing large-scale trial. Preliminary analysis, conducted by an independent data monitoring board, looked at 94 infections recorded so far in the vaccine’s phase 3 study, which has enrolled nearly 44,000 people in the US and five other countries. Of those participants who were infected with COVID-19, it is currently unclear how many had received the vaccine versus those who had been given a placebo. The current efficacy rate, which is much better than most experts expected, implies that no more than eight volunteers will have been inoculated. The data have yet to be peer-reviewed, and Pfizer said the initial protection rate might change by the time the study ends. The longevity of the immune response provoked by the mRNA-based vaccine also remains unknown. However, the findings are the most promising indication to date that a vaccine will be effective in preventing disease among infected individuals, handing humanity a crucial tool in tackling the pandemic. Pfizer and its German partner BioTech will continue with the phase 3 trial until 164 infections have been reported among volunteers - a figure that will give regulatory authorities a clearer idea of the vaccine’s efficacy. This number is expected to be reached by early December in light of the rising US infection rates, Pfizer said. The two companies said they have so far found no serious safety concerns and expect to seek US emergency use authorisation later this month. Read full story Source: The Independent, 9 November 2020
  5. Event
    Streamline your policy management workflow in the cloud with PolicyStat. From single hospitals to multi-facility organisations, all your policies and procedures are in one easily accessible library and always kept current. Efficiently organise and govern policies, procedures and related documentation . Stay compliant and audit ready to avoid penalties and drive better outcomes. Optimise policy workflows and change management to improve performance. Align culture, process and people for better document control and regulatory compliance. Register
  6. Content Article
    The report concludes with short, medium and long-term measures that support both immediate and future responses as the NHS continues to tackle the virus. The measures include eight national safety recommendations, safety observations and a tool that NHS trusts can use straight away to review their approach. Safety recommendations 1: It is recommended that the Department of Health and Social Care, working with NHS England and NHS Improvement, Public Health England, and other partners as appropriate, develops a transparent process to co-ordinate the development, dissemination and implementation of national guidance across the healthcare system to minimise the risk of nosocomial transmission of COVID-19. 2: It is recommended that NHS England and NHS Improvement supports additional capacity for testing for NHS patients and staff (Pillar 1 testing) facilitates the accessibility of rapid testing for NHS trusts, as soon as an increase in rapid testing supplies becomes available. 3: It is recommended that NHS England and NHS Improvement: develops a national intensive infection prevention and control (IPC) safety support programme for COVID-19 which focuses on leadership, IPC technical support, education, practice, guidance and assurance develops a national IPC strategy which focuses on developing IPC capacity, capability and sustainability across the NHS in England. 4: It is recommended that NHS England and NHS Improvement reviews the principles of the hierarchy of controls in its health building notes (HBN) and health technical memoranda (HTM) for the design of the built environment in existing and new hospital estate to reduce the risk of nosocomial transmission. 5: It is recommended that NHS England and NHS Improvement responds to emerging scientific evidence and shared learning when reviewing guidance for NHS trusts on the role of hospital ventilation systems in nosocomial transmission. 6: It is recommended that NHS England and NHS Improvement investigates and evaluates the risks associated with the potential impact of staff fatigue and emotional distress on nosocomial transmission of COVID-19. 7: It is recommended that the Department of Health and Social Care reviews and identifies the mechanisms which enabled regional and local organisations to adapt and respond with agility during the pandemic. This should inform the development of a strategic approach to national leadership models at times of crisis and under normal conditions. 8: It is recommended that NHSX considers how technology can assist in mitigating nosocomial transmission in the ward environment with regard to: the use of digital communication technologies in assisting with the deployment of staff and the dissemination and circulation of key information the increased use and availability of personal computing devices and electronic health record systems.
  7. Event
    Data and Information have been and continues to be a crucial and integral part of the health services fight against COVID-19. Data and patient information are constantly being used in new ways to help to care for people and help the NHS and social care to better understand and respond to the virus. NHS England along with NHSX are currently using data as evidence to help shape new care models and keep the public safe from the COVID-19 virus. The newly established NHS COVID-19 Data Store will provide a high-value tool for helping NHS monitor data sets and establish trends. This data can be used to look at several things such as bed capacity in hospitals or the number of ventilators available in a specific area. Our Developing new care models: The NHS Virtual Data & Information Congress will provide delegates with an interactive overview of this new Data Store and share best practices from across the UK. Key data-driven topics include; • Using health data responsibly and safely for research and innovation • Supporting vulnerable people (GP Records) • Remote patient monitoring • Security and regulation • Much more... Register
  8. Content Article
    The purpose of this review from Hutchinson et al. was to systematically examine published and grey research reports in order to assess the state of the science regarding the validity and reliability of the RAI-MDS 2.0 Quality Indicators (QIs). The authors found that evidence for the reliability and validity of the RAI-MDS QIs remains inconclusive. The QIs provide a useful tool for quality monitoring and to inform quality improvement programs and initiatives. However, caution should be exercised when interpreting the QI results and other sources of evidence of the quality of care processes should be considered in conjunction with QI results.
  9. Content Article
    Research shows that patient complaints are significantly associated with physicians' risk management activity and lawsuits. Research also demonstrates that a small subset of physicians and surgeons in various areas of practice are associated with disproportionate shares of patient complaints. Coded and aggregated patient complaint data therefore offer a metric for identifying and promoting behavior change. Analysis of the distribution of patient complaints associated with 41 paediatric cardiac surgeons is presented as a means for helping leaders show one surgeon how her/his risk status compares with peers. The paper describes a specific plan and reliable process by which medical group/centre colleagues and leaders may: address lapses in professionalism and performance; follow-up to promote professionalism, professional accountability, quality, and a safety culture; and reduce risk.
  10. Content Article
    The Covid Symptom Study led by King’s College London, underpinned by a self-reporting app from health-science company ZOE, has involved more than 4 million users in the UK and is being used to track and monitor COVID-19 symptoms over time. Researchers have used this data since 24 March to study the patterns and duration of COVID-19 symptoms. In this paper from the Tony Blair Institute for Global Change, combined data from the King's College London Covid Symptom Study with emerging evidence from the broader scientific community to understand what we do and – as importantly – don’t know about those suffering with long-term symptoms of COVID-19. The Covid Symptom Study is unique as it has one of the largest sample sizes of COVID-19 studies with more than 4 million participants, but it is important to note that the data is collected and analysed based on self-reported symptoms recorded through an app. New findings from the study, which will be published in full by King’s College later this month, indicate that around 10% of those taking part in the survey had symptoms of long Covid for a month, with between 1.5% and 2% still experiencing them after three months. Extrapolating from this, the researchers believe that of those affected by the first wave of the virus in the UK, 300,000 people would have had Covid symptoms for a month and 60,000 for three months or more. Properly understanding the scope and scale of the issue of long Covid is critical in both communicating and balancing the overall risk of the virus, particularly as governments determine their next steps in containing COVID-19 and avoiding a full lockdown.
  11. Content Article
    Impacts of the pandemic may be direct from COVID-19 or may be indirect from changes to the healthcare system or lockdown measures. The paper conceptualises harm to health using the following four categories: A. Health impacts from contracting COVID-19 (A) B. Health outcomes for COVID-19 worsened because of lack of NHS critical care capacity (B) C. Health impacts from changes to health and social care made in order to respond to COVID19, such as changes to emergency care (C1), changes to adult social care (C2), changes to elective care (C3) and changes to primary and community care (C4). D. Health impacts from factors affecting the wider population, both from social distancing measures (D1) and the economic impacts increasing deprivation (D2). The results are briefly discussed in the section below; summary tables of the mortality and morbidity impacts can also be found below.
  12. Event
    Free from the Patient Safety Movement offered for physicians, pharmacists, and nurses. This activity has been approved for AMA PRA Category 1 Credits™, ANCC contact hours, and ACPE contact hours. Registration
×